We seek well-defined investment opportunities at all development stages - from early seed capital to expansion-stage financing
We seek well-defined investment opportunities at all development stages - from early seed capital to expansion-stage financing
Cardiosolutions, Inc. is a development stage company focused on a novel alternative to open heart surgery to solve the problem of mitral and tricuspid valve regurgitation. The company is developing a pioneering technology, the Mitra-Spacer™, designed to deliver an implant that will provide a sealing surface for the leaflets of the mitral valve, thereby significantly reducing or eliminating mitral regurgitation (MR). The technology is also readily transferable to the tricuspid valve for those patients with untreated tricuspid regurgitation. The company’s goal is to provide a new therapeutic alternative delivered in a minimally invasive procedure for a wide range of patients of all ages who suffer from moderate to severe mitral and tricuspid regurgitation, including a portion of those who are currently in congestive heart failure. Its less invasive procedure has the potential to substantially reduce procedure time, expedite patient recovery and provide a less costly alternative to current treatment options.
X CLOSE
For centuries, suture repair has been the standard of care to surgically address damaged or torn tendons. Despite advancements in biomaterials, operative techniques and post-rehabilitation protocols, complications following suture repair of tendons remain commonplace. The CoNextions TR tendon repair system provides significant improvements in procedure efficiency, as well as repair strength. Using a proprietary stainless steel tissue staple, the CoNextions TR has demonstrated a 2-3 times increase in tensile strength compared to conventional suture repair in cadaveric studies. This increase in repair strength could lead to earlier physical therapy, and thereby reduce adhesion formation and provide increased range of motion.
X CLOSE
Deep Vein Medical is developing an implantable prosthetic vein valve to provide one of the first curative treatment options for individuals suffering from chronic venous insufficiency that often leads to deep vein thrombosis. Existing therapies addressing this disorder are palliative, treating only the symptoms of the underlying disease. The company’s valve is constructed using biocompatible materials, is designed to limit the back flow of blood into the lower extremities, and can be delivered using a minimally invasive percutaneous catheter approach.
X CLOSE
Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The Cordella™ Heart Failure System includes a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. The seamlessly integrated system enables proactive management and early detection of worsening heart failure, which promotes ongoing therapeutic interventions to improve quality of life, reduce hospital readmissions, and lower care costs.
X CLOSE
HydroCision, Inc. is focused on improving surgical outcomes by adapting its proprietary water jet technology to various applications. Specifically, it has developed a method of controlling a hair-thin, supersonic stream of sterile saline solution, while simultaneously enabling an accompanying Venturi suction system to cut and selectively remove tissue of various densities from a surgical site in a minimally invasive manner. The company has designed, and is currently marketing, single-use, hand piece surgical instruments to hold, cut, sculpt, or ablate tissue faster and with greater precision than other surgical modalities. This method is proving to enhance both clinical and health economic outcomes in multiple fields of surgery and is currently sold for applications in minimally invasive tenotomy procedures, as well as for spinal and sports medicine procedures.
X CLOSE
Locemia Solutions was a privately-held specialty pharma company located in Montreal. The company developed an innovative delivery system for glucagon to make severe hypoglycemia rescue as simple as a puff in the nose for insulin users worldwide. Locemia developed the drug-device combination through completion of Phase III studies. Eli Lilly purchased the company in 2015 and will commercialize the Locemia product.
X CLOSE
POC Medical Systems has developed a versatile technology platform to rapidly screen for disease using a minimal amount of blood. Their PandoraCDx portable system uses microfluidics to deliver a test-to-result time of 15 minutes. The first application, MammoAlert, is a breast cancer screening tool currently being developed for those regions of the world where mammography is not used for screening due to cost, difficulty of access or cultural sensitivity. The company plans to commercialize this product beginning in India, to be followed by other countries and regions. Future applications may include a screening test for myocardial infarction, cervical cancer, oral cancer, and an oncology panel.
X CLOSE
Rachiotek has developed and is commercializing the Stabilimax Dynamic Spine Stabilization System, a biomechanically superior motion-preserving device to treat disorders of the lumbar spine (including spinal stenosis). Stabilimax stabilizes the spine, while allowing for spinal movement in patients with moderate-to-severe functional impairment following spinal decompression surgery. Stabilimax has substantial human clinical data compiled over seven years post-implant showing predictable and successful clinical outcomes (including pain reduction and functional improvement) and the absence of device-related complications. Radiographic images of these patients have provided further evidence of a reduction in adjacent level issues commonly seen with traditional spinal fusion.
X CLOSE
Verax has developed and is commercializing a highly sensitive test that accurately and rapidly detects bacterial contamination in blood units prior to transfusion, the largest human health risk associated with this procedure. The company’s FDA cleared test, known as Verax Platelet PGD (pan genera detection), detects a broad array of both Gram-positive and Gram-negative bacterial contaminants commonly found in blood components, including platelets. In addition, the company’s technology has broader applications in cell therapies and dialysis testing.
X CLOSE
BRAINBox Solutions is developing the first AI enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion. The company seeks to establish a clinical best practice standard for the diagnosis and prognosis of concussion. The product incorporates a panel of proprietary, patented blood biomarkers which can be read immediately on a point of care instrument or using standard laboratory systems, as well as neurocognitive testing, to provide a single system score that measures the severity of the injury and guide treatment. The company is led by key physician and scientific thought leaders in the field and an experienced, clinically focused management team. The initial product will be used by physicians in emergency room and urgent care settings.
X CLOSE
SonoMotion has developed an ultrasound-based platform technology for treating patients with kidney stones. The company’s initial product, StoneClear, uses pulsed ultrasound, integrated into a conventional imaging system, to push kidney stones out of the ureter and into either the bladder or back into the kidney, thereby restoring the flow of urine and immediately eliminating the pain without the use of opioids or other prescription pain medicine. The company’s second system, BreakWave, uses a similar ultrasound modality to break stones in the kidney or ureter and allowing them to pass freely from the body.
X CLOSE
Epharmix is a digital health company that has developed a text-based tool to automate patient care management functions for caregivers, including hospitals and physicians. The digital tools, covering 25 chronic disease states and conditions, collect condition specific information and triage high-risk and rising-risk patients to identify those who require urgent attention. The company has partnered with a number of leading medical researchers at Washington University in St. Louis and elsewhere, as well as healthcare providers and payers, to develop the medical and clinical foundations underlying its digital communications. The preset text messages are timely and are proving to be effective at engaging patients, which has led to increased compliance and improved clinical outcomes for patients and greater productivity for healthcare providers.
X CLOSE
UID has developed and is commercializing an RFID-based system for automating the tracking, collection and analysis of animals and testing data. UID’s proprietary suite of readers, tags and software revolutionizes the age-old practice of manual data entry and animal identification. Specifically, the company uses programmable, implantable microchips and transponders that aid in identifying and monitoring laboratory mice, rats and other animals. In addition, the company’s software enables automated data collection associated with animal and sample-based research. In addition to its core business of supporting research applications for biopharmaceutical companies and universities, the company’s technology is being used in several industrial applications for tracking large assets.
X CLOSE